A randomized double-blind, placebo-controlled, multi center, parallel group pilot study of the safety and efficacy of hydrocortisone acetate suppositories, 25 mg compared to placebo suppositories in the treatment of symptomatic internal hemorrhoids

ivagen Pharmaceuticals Inc0 个研究点目标入组 37 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•a. Have a diagnosis of internal hemorrhoids.
•b. Is a male or female aged 18 years and older
•c. Give voluntary consent to participate in the study following a full explanation of the nature and purpose of the study, by signing the IRB-approved Informed Consent document prior to any study specific evaluations.
•d. Is willing to forego the use of non-prescription (OTC) and prescription medication or procedures for the treatment of hemorrhoidal disease and/or pain for the duration of the study.
•e. Female Subjects of childbearing potential (excluding women who are or premenarchal, surgically sterilized (by hysterectomy) or postmenopausal for at least 1 year), in addition to having a negative urine pregnancy test, must be willing to use an acceptable form of birth control during the study from the day of the first dose administration to 30 days after the last administration of study drug. Subjects on hormonal contraception must be stabilized on the same type prior to enrollment in the study and must not change the method during the study.
•f. All male Subjects must agree to use accepted methods of birth control with their partners. Female partners should use an acceptable method of birth control as described in the above Item

•a. Has inflammatory bowel disease.
•b. Is immunocompromised (e.g. receiving cancer chemotherapy, steroids, HIV positive).
•c. Is a pregnant or nursing female.
•d. Subjects who have unstable medical disorders that are clinically significant or have life-threatening diseases.
•e. Subjects who consume excessive amounts of alcohol (greater than two drinks per day) or use drugs of abuse (including, but not limited to, cannabinoids, cocaine and barbiturates).
•f. Positive urine screening for drugs of abuse or positive alcohol breath test.
•g. Subjects who have participated in an investigational drug study (i.e., Subjects have been treated with an investigational drug) Lacks suitability for participation in this study for any reason in the opinion of the Investigator.
•h. Clinically significant complete blood count (CBC), comprehensive metabolic panel (CMP), urinalysis or positive HIV, Hepatitis B, Hepatitis C.

发起方

ivagen Pharmaceuticals Inc